RTTNews | Jul 22, 2021 08:17AM EDT

08:17 Thursday, July 22, 2021 (RTTNews.com) - Shares of Seres Therapeutics, Inc. (MCRB) are down more than 55% in pre-market on Thursday after the company said Phase 2 study of its ulcerative colitis drug candidate failed to meet the primary endpoint.

In Phase 2b study dubbed Eco-Reset, SER-287, proposed for the treatment of patients with mild-to-moderate ulcerative colitis, did not meet the primary endpoint of improving clinical remission rates compared to placebo, the company said.

As Eco-Reset failed to meet the pre-defined target, the company has decided to close the open label and maintenance portions of the study.

MCRB closed Wednesday's trade at $20.83, up 0.48%. The stock is currently at $9.16.

Read the original article on RTTNews ( https://www.rttnews.com/3211125/seres-therapeutics-plunges-in-pre-market-on-ulcerative-colitis-therapy-not-meeting-expectations.aspx)

For comments and feedback: contact editorial@rttnews.com

Copyright(c) 2021 RTTNews.com All Rights Reserved